Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaxPA: Baxdrostat in Primary Aldosteronism
jRCT2071250115Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in primary aldosteronism (PA) comparing Baxdrostat arm with Placebo arm (2 arms). Primary endpoints: Change from baseline in seated systolic blood pressure at Week 8 and Normalization of RAAS at Week 8. Started Sep 2025; status: completed.
02
Drugs
baxdrostat
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on jRCT2071250115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250115.